NZ597252A - Compounds for inhibiting mitotic progression - Google Patents

Compounds for inhibiting mitotic progression

Info

Publication number
NZ597252A
NZ597252A NZ597252A NZ59725207A NZ597252A NZ 597252 A NZ597252 A NZ 597252A NZ 597252 A NZ597252 A NZ 597252A NZ 59725207 A NZ59725207 A NZ 59725207A NZ 597252 A NZ597252 A NZ 597252A
Authority
NZ
New Zealand
Prior art keywords
cancer
lymphoma
kinase inhibitor
aurora kinase
leukemia
Prior art date
Application number
NZ597252A
Other languages
English (en)
Inventor
Christopher F Claiborne
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ597252(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Priority to NZ611898A priority Critical patent/NZ611898A/en
Publication of NZ597252A publication Critical patent/NZ597252A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ597252A 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression NZ597252A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ611898A NZ611898A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
NZ577042A NZ577042A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
NZ597252A true NZ597252A (en) 2013-06-28

Family

ID=39315133

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ597252A NZ597252A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression
NZ611898A NZ611898A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression
NZ577042A NZ577042A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ611898A NZ611898A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression
NZ577042A NZ577042A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Country Status (35)

Country Link
US (6) US8026246B2 (zh)
EP (4) EP2497772B1 (zh)
JP (3) JP5102839B2 (zh)
KR (2) KR101110458B1 (zh)
CN (2) CN103483343B (zh)
AR (1) AR064246A1 (zh)
AT (1) ATE556076T1 (zh)
AU (1) AU2007322046B2 (zh)
BR (1) BRPI0718803B8 (zh)
CA (1) CA2669680C (zh)
CL (1) CL2007003244A1 (zh)
CR (3) CR10782A (zh)
CY (1) CY1112828T1 (zh)
DK (2) DK2086981T3 (zh)
EA (1) EA015779B1 (zh)
ES (3) ES2537451T3 (zh)
GE (1) GEP20125459B (zh)
HK (4) HK1134672A1 (zh)
HR (2) HRP20120490T1 (zh)
IL (1) IL198690A0 (zh)
MA (1) MA30988B1 (zh)
MX (3) MX348568B (zh)
MY (1) MY153243A (zh)
NO (1) NO343338B1 (zh)
NZ (3) NZ597252A (zh)
PH (1) PH12012502057A1 (zh)
PL (2) PL2086981T3 (zh)
PT (2) PT2497772E (zh)
RS (2) RS52313B (zh)
SG (2) SG176443A1 (zh)
SI (2) SI2497772T1 (zh)
TW (1) TWI401255B (zh)
UA (1) UA94129C2 (zh)
WO (1) WO2008063525A1 (zh)
ZA (1) ZA200903279B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111039A2 (en) * 2004-05-14 2005-11-24 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AR074487A1 (es) * 2008-12-05 2011-01-19 Millennium Pharm Inc Tiolactamas inhibidoras de proteinquinasas plk, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de trastornos proliferativos e inflamatorios, en particular cancer.
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CA2788774A1 (en) * 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US9085582B2 (en) * 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
TW201316991A (zh) 2011-06-03 2013-05-01 Millennium Pharm Inc Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
JP2018502089A (ja) * 2014-12-23 2018-01-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗がん剤としての複素環式の限定された三環系スルホンアミド
CN108349943A (zh) 2015-09-09 2018-07-31 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
KR20230042756A (ko) 2016-03-15 2023-03-29 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
US20240108618A1 (en) 2022-06-30 2024-04-04 Eli Lilly And Company Kras g12c inhibitor dosing regimens

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CA2247453A1 (en) * 1996-03-08 1997-09-12 Joseph James Lewis Azolobenzazepine derivatives as neurologically active agents
JP2001507349A (ja) * 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US6372735B1 (en) * 1997-09-29 2002-04-16 Meiji Seika Kaisha, Ltd. Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
WO2000067754A1 (en) 1999-05-12 2000-11-16 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
ATE403644T1 (de) 1999-12-06 2008-08-15 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
JP4160395B2 (ja) 2000-12-21 2008-10-01 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
JP4364637B2 (ja) 2001-08-09 2009-11-18 アクテリオン ファーマシューティカルズ リミテッド 新規なベンゾ縮合へテロ環化合物
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005111039A2 (en) 2004-05-14 2005-11-24 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
RU2007122485A (ru) 2004-11-17 2008-12-27 Мийкана Терапьютикс Ингибиторы киназы
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
BRPI0620341A2 (pt) 2005-12-23 2011-11-08 Smithkline Beecham Corparation azaindóis inibidores de cinases aurora
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
PL2086981T3 (pl) 2012-09-28
NO20091864L (no) 2009-06-15
EP2086981B1 (en) 2012-05-02
EP2944639B1 (en) 2017-01-04
IL198690A0 (en) 2010-02-17
KR101110458B1 (ko) 2012-03-13
US20110312943A1 (en) 2011-12-22
CY1112828T1 (el) 2016-02-10
JP5452811B2 (ja) 2014-03-26
WO2008063525A1 (en) 2008-05-29
JP2012006965A (ja) 2012-01-12
US10836766B2 (en) 2020-11-17
CA2669680C (en) 2012-04-10
CN103483343B (zh) 2016-06-01
NZ577042A (en) 2012-03-30
EA015779B1 (ru) 2011-12-30
CN103483343A (zh) 2014-01-01
EA200970486A1 (ru) 2009-10-30
MX348568B (es) 2017-06-20
AR064246A1 (es) 2009-03-25
ATE556076T1 (de) 2012-05-15
SI2086981T1 (sl) 2012-12-31
BRPI0718803B1 (pt) 2020-11-17
JP2014055166A (ja) 2014-03-27
HRP20150047T1 (en) 2015-03-13
KR20090091173A (ko) 2009-08-26
CL2007003244A1 (es) 2008-04-04
US11958855B2 (en) 2024-04-16
NZ611898A (en) 2015-01-30
NO343338B1 (no) 2019-02-04
SI2497772T1 (sl) 2015-03-31
DK2497772T3 (en) 2015-01-19
EP2497773B1 (en) 2015-02-25
US9988384B2 (en) 2018-06-05
US8026246B2 (en) 2011-09-27
ES2537451T3 (es) 2015-06-08
BRPI0718803B8 (pt) 2021-05-25
ES2384123T3 (es) 2012-06-29
SG10201503350TA (en) 2015-06-29
AU2007322046A1 (en) 2008-05-29
EP2497772B1 (en) 2014-10-29
EP2944639A1 (en) 2015-11-18
EP2497772A1 (en) 2012-09-12
CA2669680A1 (en) 2008-05-29
KR101342014B1 (ko) 2013-12-19
BRPI0718803A2 (pt) 2013-12-03
DK2086981T3 (da) 2012-08-06
CN101547924A (zh) 2009-09-30
CR20140544A (es) 2015-01-12
PH12012502057B1 (en) 2015-09-14
TWI401255B (zh) 2013-07-11
MA30988B1 (fr) 2009-12-01
JP2010510215A (ja) 2010-04-02
UA94129C2 (ru) 2011-04-11
PL2497772T3 (pl) 2015-05-29
MX343391B (es) 2016-11-04
US20080167292A1 (en) 2008-07-10
KR20110113210A (ko) 2011-10-14
GEP20125459B (en) 2012-03-26
US20190031662A1 (en) 2019-01-31
ZA200903279B (en) 2010-07-28
ES2528793T3 (es) 2015-02-12
TW200829589A (en) 2008-07-16
HRP20120490T1 (hr) 2012-07-31
US20150166545A1 (en) 2015-06-18
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
AU2007322046B2 (en) 2012-04-05
EP2086981A1 (en) 2009-08-12
HK1175778A1 (zh) 2013-07-12
RS53788B1 (en) 2015-06-30
HK1134672A1 (en) 2010-05-07
JP5102839B2 (ja) 2012-12-19
EP2497773A1 (en) 2012-09-12
RS52313B (en) 2012-12-31
CR10782A (es) 2009-06-24
HK1217699A1 (zh) 2017-01-20
SG176443A1 (en) 2011-12-29
MY153243A (en) 2015-01-29
CR20140154A (es) 2014-07-23
CN101547924B (zh) 2013-09-25
US9765076B2 (en) 2017-09-19
HK1175777A1 (zh) 2013-07-12
US20210214361A1 (en) 2021-07-15
PH12012502057A1 (en) 2015-09-14
PT2497772E (pt) 2015-02-05
US20110312942A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
NZ597252A (en) Compounds for inhibiting mitotic progression
CA2649549A1 (en) Methods of treating cell proliferative disorders by using pyrimidinediamine compounds
RU2441005C2 (ru) Новые пиразолопиримидины как ингибиторы циклинзависимых киназ
JP2012082234A5 (zh)
NZ598521A (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
TR201800962T4 (en) CDC7 KINAZI INHIBITORS AND THEIR USAGE
IL273432B (en) Protein compounds and their uses
NZ596301A (en) Novel 7-deazapurine nucleosides for therapeutic uses
NZ590431A (en) Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
WO2005084712A3 (en) Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
WO2004087713A8 (en) Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
WO2008094909A3 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
MY146474A (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
RS20080002A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
PL1678166T3 (pl) Inhibitory kinaz białkowych
HUP0401047A2 (hu) Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények
MX2009003941A (es) Derivados de 3-(dihidro-1h-pirazolo[4,3-d]pirimidin-5-il)-4-propox ibencenosulfonamida y metodos de uso.
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
TW200745130A (en) 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2018152548A4 (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
MY154591A (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
NZ589269A (en) Combination therapy with an antitumor alkaloid

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 NOV 2014 BY HENRY HUGHES

Effective date: 20140114

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2015 BY COMPUTER PACKAGES INC

Effective date: 20141018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2016 BY COMPUTER PACKAGES INC

Effective date: 20160119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2017 BY COMPUTER PACKAGES INC

Effective date: 20161101

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2018 BY COMPUTER PACKAGES INC

Effective date: 20171018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2019 BY COMPUTER PACKAGES INC

Effective date: 20181018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2020 BY COMPUTER PACKAGES INC

Effective date: 20191018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2021 BY COMPUTER PACKAGES INC

Effective date: 20201020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2022 BY COMPUTER PACKAGES INC

Effective date: 20211017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2023 BY ANAQUA SERVICES

Effective date: 20221022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2024 BY ANAQUA SERVICES

Effective date: 20231020